Source:http://linkedlifedata.com/resource/umls/id/C0060389
MSH: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.,CSP: orally active testosterone 5-alpha reductase inhibitor, used as an alternative to surgery for treatment of benign prostatic hyperplasia.,NCI: A drug used to reduce the amount of male hormone (testosterone) produced by the body.,PDQ: A synthetic 4-azasteroid compound. Finasteride competitively binds to and inhibits steroid type II 5-alpha-reductase in the prostate gland, liver, and skin, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone (DHT) and reducing serum DHT levels. The reduction in serum DHT levels results in diminished stimulation of androgen receptors in the nuclei of prostate cells and, so, diminished prostate cell proliferation. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41096&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41096&idt